Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Zelira Therapeutics ( (AU:ZLD) ) just unveiled an update.
Zelira Therapeutics has enhanced its financial flexibility by receiving a $1.15 million R&D Tax Incentive refund and establishing a $1 million At-the-Market funding facility. These financial moves support its ongoing development programs, including preparations for the FDA clinical trial of HOPE® 1. The company also completed the full conversion of US$3.25 million convertible notes into equity, strengthening its capital structure. The development of capsule formulations for HOPE® and Zenivol® using Zyraydi™ technology is on track for completion in mid to late 2025, aligning with Zelira’s strategy to enhance product consistency and market readiness.
More about Zelira Therapeutics
Zelira Therapeutics Ltd is a global leader in the development and commercialization of clinically validated cannabinoid-based medicines. The company focuses on advancing its pipeline of cannabinoid-based therapies, with a strong emphasis on clinical validation and market readiness.
YTD Price Performance: -21.32%
Average Trading Volume: 279
Technical Sentiment Signal: Buy
Current Market Cap: $2.66M
See more insights into ZLD stock on TipRanks’ Stock Analysis page.